Literature DB >> 10486027

Core decompression in osteonecrosis of the femoral head: risk-factor-dependent outcome evaluation using survivorship analysis.

H G Simank1, D R Brocai, K Strauch, M Lukoschek.   

Abstract

The results of core decompression of the femoral head in the treatment of osteonecrosis are analyzed. This study includes 94 hips in 74 patients with a follow-up time ranging between 18 months and 15 years (average 6 years). There had been no need for further surgery 2 years postoperatively in 85% of the hips with preoperative Steinberg stages 0, I and II when compared with 66% with preoperative stages III, IV and V. At 4 years postoperatively the corresponding figures are 73 compared to 55%; and 6 years postoperatively 69 compared to 49%. This difference was significant (P=0.0402). Further significant risk factors are corticosteroid administration, smoking and alcohol intake. The results of core decompression are good when the preoperative lesion is at Steinberg stage 0, I and II and the patient does not present with other risk factors. In cases with risk factors the outcome is significantly less good. The procedure is not indicated in the presence of advanced disease.

Entities:  

Mesh:

Year:  1999        PMID: 10486027      PMCID: PMC3619822          DOI: 10.1007/s002640050335

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  15 in total

1.  A current review of core decompression in the treatment of osteonecrosis of the femoral head.

Authors:  Todd P Pierce; Julio J Jauregui; Randa K Elmallah; Carlos J Lavernia; Michael A Mont; James Nace
Journal:  Curr Rev Musculoskelet Med       Date:  2015-09

Review 2.  Which factors influence preservation of the osteonecrotic femoral head?

Authors:  Jay R Lieberman; Stephen M Engstrom; R Michael Meneghini; Nelson Fong SooHoo
Journal:  Clin Orthop Relat Res       Date:  2012-02       Impact factor: 4.176

3.  Bilateral idiopathic osteonecrosis of the major tubercle of the humerus.

Authors:  Julian Dexel; Philip Kasten
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2012-05-01       Impact factor: 4.342

4.  SAS weekly rounds: avascular necrosis.

Authors:  Thomas W Hamilton; Susan M Goodman; Mark Figgie
Journal:  HSS J       Date:  2009-03-18

Review 5.  [Pain management in non-juvenile, aseptic osteonecrosis].

Authors:  M Jäger; A Werner; S Lentrodt; U Mödder; R Krauspe
Journal:  Schmerz       Date:  2004-12       Impact factor: 1.107

6.  MRI-guidance in percutaneous core decompression of osteonecrosis of the femoral head.

Authors:  Pekka Kerimaa; Matti Väänänen; Risto Ojala; Pekka Hyvönen; Petri Lehenkari; Osmo Tervonen; Roberto Blanco Sequeiros
Journal:  Eur Radiol       Date:  2015-08-01       Impact factor: 5.315

Review 7.  Do modern techniques improve core decompression outcomes for hip osteonecrosis?

Authors:  David R Marker; Thorsten M Seyler; Slif D Ulrich; Siddharth Srivastava; Michael A Mont
Journal:  Clin Orthop Relat Res       Date:  2008-04-08       Impact factor: 4.176

8.  One-sided hip-preserving and concurrent contralateral total hip arthroplasty for the treatment of bilateral osteonecrosis of the femoral head in different stages: short-medium term outcomes.

Authors:  Yirong Zeng; Xinyu Qi; Wenjun Feng; Jie Li; Feilong Li; Jianchun Zeng; Chunzhi Yi; Jinlun Chen
Journal:  BMC Musculoskelet Disord       Date:  2015-06-05       Impact factor: 2.362

Review 9.  Bone regeneration: stem cell therapies and clinical studies in orthopaedics and traumatology.

Authors:  Enrique Gómez-Barrena; Philippe Rosset; Ingo Müller; Rosaria Giordano; Carmen Bunu; Pierre Layrolle; Yrjö T Konttinen; Frank P Luyten
Journal:  J Cell Mol Med       Date:  2011-06       Impact factor: 5.310

10.  Rationale for prostaglandin I2 in bone marrow oedema--from theory to application.

Authors:  Marcus Jäger; Frank Peter Tillmann; Thomas S Thornhill; Marcus Mahmoudi; Dirk Blondin; Gerd Rüdiger Hetzel; Christoph Zilkens; Rüdiger Krauspe
Journal:  Arthritis Res Ther       Date:  2008-10-03       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.